About Leucine-zipper-like transcriptional regulator 1
Leucine-zipper-like transcriptional regulator 1 (LZTR1) is a protein
from Homo sapiens identified by UniProt accession
Q8N653, 840 residues long.
MolForge cross-references it against 0 known binders and
268 disease associations.
Target properties
| Protein name | Leucine-zipper-like transcriptional regulator 1 |
| UniProt accession | Q8N653 |
| Gene | LZTR1 |
| Organism | Homo sapiens |
| Length | 840 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N653-F1 | alphafold | PREDICTED | 80.01 | — |
Amino-acid sequence (840 residues)
MAGPGSTGGQ IGAAALAGGA RSKVAPSVDF DHSCSDSVEY LTLNFGPFET VHRWRRLPPC DEFVGARRSK HTVVAYKDAI YVFGGDNGKT MLNDLLRFDV KDCSWCRAFT TGTPPAPRYH HSAVVYGSSM FVFGGYTGDI YSNSNLKNKN DLFEYKFATG QWTEWKIEGR LPVARSAHGA TVYSDKLWIF AGYDGNARLN DMWTIGLQDR ELTCWEEVAQ SGEIPPSCCN FPVAVCRDKM FVFSGQSGAK ITNNLFQFEF KDKTWTRIPT EHLLRGSPPP PQRRYGHTMV AFDRHLYVFG GAADNTLPNE LHCYDVDFQT WEVVQPSSDS EVGGAEVPER ACASEEVPTL TYEERVGFKK SRDVFGLDFG TTSAKQPTQP ASELPSGRLF HAAAVISDAM YIFGGTVDNN IRSGEMYRFQ FSCYPKCTLH EDYGRLWESR QFCDVEFVLG EKEECVQGHV AIVTARSRWL RRKITQARER LAQKLEQEAA PVPREAPGVA AGGARPPLLH VAIREAEARP FEVLMQFLYT DKIKYPRKGH VEDVLLIMDV YKLALSFQLC RLEQLCRQYI EASVDLQNVL VVCESAARLQ LSQLKEHCLN FVVKESHFNQ VIMMKEFERL SSPLIVEIVR RKQQPPPRTP LDQPVDIGTS LIQDMKAYLE GAGAEFCDIT LLLDGHPRPA HKAILAARSS YFEAMFRSFM PEDGQVNISI GEMVPSRQAF ESMLRYIYYG EVNMPPEDSL YLFAAPYYYG FYNNRLQAYC KQNLEMNVTV QNVLQILEAA DKTQALDMKR HCLHIIVHQF TKVSKLPTLR SLSQQLLLDI IDSLASHISD KQCAELGADI
Explore Leucine-zipper-like transcriptional regulator 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets